Molecular diagnostics firm Biocartis won a €750,000 grant (approximately $796,000) from the Flanders Organization for Innovation & Entrepreneurship (VLAIO) to support the development of a fully ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Idylla CDx MSI test — a fully automated, “sample-to-result” companion diagnostic — for ...
Call it the laptop that would not die. We just crowned our first PCMag Lab Award winner for best battery life, an MSI ...
Mechelen, Belgium, 10 March 2026 – Today, Biocartis announced that its Idylla™ CDx MSI Test has received Class C companion diagnostic (CDx) certification under the EU’s IVDR 1 as a CDx for colorectal ...
New diagnostic test for MSI in solid tumors can inform physicians on immuno-oncology therapies, and can guide treatment decisions for patients with Lynch-associated cancers LEIDEN, Netherlands & ...
Screening cancer patients for microsatellite instability (MSI) can provide pathologists, oncologists, and patients with information that characterizes tumors to help guide care and make more informed ...
Validity of 1% Hormonal Receptor Positivity Cutoff by the ASCO/College of American Pathologists Guidelines at the Georgia Cancer Center In 658 patients with advanced GI cancers who underwent both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results